Overview
OneSkin develops premium skincare products centered on its OS-01 peptide, designed to slow skin aging by targeting cellular senescence. The OS-01 peptide prevents buildup of aged cells, supports tissue repair, and boosts collagen and hyaluronic acid production, with lab tests showing thicker epidermis and a ~2.5-year reduction in biological skin age in five days. It differentiates itself by using senotherapy-based science, validated in lab skin models, a science-forward peptide platform, and a mix of direct-to-consumer subscriptions, Amazon sales, and professional channels, led by four female scientists. The company aims to expand internationally, launch new products, and advance clinical studies to further validate OS-01 and related therapies for longer-lasting skin health.
Work here?Claim your company
Simplify's take
What believers are saying
- OneSkin raised $20.4 million in June 2025, funding clinical trials and hiring.
- 2025 revenue reached $40 million to $50 million, far above earlier estimates.
- Subscriptions and professional-channel expansion deepen retention and diversify sales beyond Amazon.
What critics are saying
- Amazon and DTC dependence exposes OneSkin to ad inflation and platform policy shifts.
- OS-01 clinical claims need repeated validation; failed studies destroy pricing power.
- If OS-01 loses credibility, OneSkin becomes a commodity moisturizer brand overnight.
What makes OneSkin unique
- OS-01 peptide claims to reduce skin biological age, anchoring OneSkin’s scientific moat.
- September 22, 2026 launch of OS-01 FACE RICH CREAM extends the longevity platform.
- Female scientist founders from Brazil built credibility across immunology, stem cells, and bioinformatics.
Help us improve and share your feedback! Did you find this helpful?